AsymAD is a preclinical phase of Alzheimer’s disease (AD) observed in ~20–30% of cognitively intact elderly individuals who nonetheless harbor substantial amyloid and Tau pathology at autopsy5–7. Here, MAPT is linked to Alzheimer disease.